PTN News

  • The PTN provides insights and updates at the 2012 BPCA annual meeting December 14, 2012 On December 4, 2012, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) staged the 2012 Best Pharmaceuticals for Children Act (BPCA) Annual Meeting in Rockville, MD. This yearly event serves as part of the NICHD mandate to oversee a priority list of needs in pediatric therapeutics under the BPCA. The BPCA ...
  • PTN acyclovir trial locks its database November 29, 2012 On September 19, 2012, the PTN locked the database for its trial of the pharmacokinetics of acyclovir in infants. Database lock means that all clinical trial data have been reviewed, queries have been resolved and issues addressed, and the database cannot be altered in any way. Acyclovir is approved by the U.S. Food and Drug Administration ...
  • PTN Acyclovir Trial Completes Enrollment November 29, 2012 On June 1, 2012, the PTN completed enrollment into its trial of the pharmacokinetics of acyclovir in infants. Acyclovir is approved by the U.S. Food and Drug Administration for herpes simplex virus (HSV) infections in babies. HSV is a very serious infection in this vulnerable group, often resulting in death or profound mental retardation. To date, ...
  • BPCA Annual Meeting Coming Up in December November 2, 2012 On December 4, 2012, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will stage its annual meeting to review the prioritization list of drugs to be studied under the Best Pharmaceuticals for Children Act (BPCA). The Pediatric Trials Network (PTN) will be a key participant in this meeting as it ...
  • The PTN Mercy Method tape study locks its database October 17, 2012 The PTN’s Mercy Method™ tape study has locked its database containing information from 625 patients. Database lock means that all clinical trial data have been reviewed, queries have been resolved and issues addressed, and the database cannot be altered in any way. The trial concluded enrollment in April of this year. The Mercy Method™—developed at Children’s ...
  • PTN hydroxyurea trial opens enrollment to younger participants July 26, 2012 The PTN hydroxyurea trial has extended enrollment into Arm 1 of the study, which will target participants ages 2 to ≤5 years. Enrollment into this trial is proceeding in two stages: the first stage (Arm 2) is focusing on children 5 to 17 years of age. Fourteen of 24 participants have been enrolled into this arm ...
  • PTN lisinopril study enrolls first participant June 25, 2012 Principal investigator Daniel Feig, MD, PhD, of University of Alabama-Birmingham has successfully enrolled the first participant into the PTN study of lisinopril use for the control of high blood pressure in kids with kidney transplants. Seven sites are currently recruiting participants into this study: Arkansas Children’s Hospital in Little Rock, Cincinnati Children’s Hospital, Children’s Mercy Hospital ...
  • PTN hydroxyurea trial prepares for interim analysis June 22, 2012 The PTN hydroxyurea trial enrolled its 7th and 8th patients on June 12 and 14, 2012, thanks to the collective efforts of Nancy Green, MD, of Columbia University Medical Center, Robert Liem, MD, of Children’s Memorial Hospital in Chicago, and Courtney Thornburg, MD, of Duke University Medical Center. Enrollment into this trial is proceeding in two ...
  • The PTN lisinopril study is now looking for participants to enroll at four active sites May 17, 2012 Four sites are now actively seeking participants to enroll into the PTN study of lisinopril for the control of high blood pressure in kids with kidney transplants: University of Alabama–Birmingham, Arkansas Children’s Hospital in Little Rock, University of Michigan at Ann Arbor, and New York University Langone Medical Center. Lisinopril is a drug used in children ...
  • The PTN lisinopril study nears the start of enrollment April 17, 2012 The PTN study of the safety and pharmacokinetics of lisinopril in pediatric kidney transplant recipients will begin enrolling patients at the end of April. At that time, 4 of the anticipated 8 sites should be activated. Lisinopril use is FDA-approved in children aged 6+ years for the treatment of high blood pressure, a condition that is ...